Published in Nat Rev Nephrol on April 17, 2012
CMX001 in Post-transplant Patients With BK Virus Viruria | NCT00793598
A cornucopia of human polyomaviruses. Nat Rev Microbiol (2013) 2.08
Structural Based Analyses of the JC Virus T-Antigen F258L Mutant Provides Evidence for DNA Dependent Conformational Changes in the C-Termini of Polyomavirus Origin Binding Domains. PLoS Pathog (2016) 1.40
New Structural Insights into the Genome and Minor Capsid Proteins of BK Polyomavirus using Cryo-Electron Microscopy. Structure (2016) 1.40
BK Polyomavirus Replication in Renal Tubular Epithelial Cells Is Inhibited by Sirolimus, but Activated by Tacrolimus Through a Pathway Involving FKBP-12. Am J Transplant (2015) 0.91
Role of cell-type-specific endoplasmic reticulum-associated degradation in polyomavirus trafficking. J Virol (2013) 0.91
Human polyomavirus reactivation: disease pathogenesis and treatment approaches. Clin Dev Immunol (2013) 0.89
The miRNA world of polyomaviruses. Virol J (2013) 0.82
Common exposure to STL polyomavirus during childhood. Emerg Infect Dis (2014) 0.81
Characterization of Immunodominant BK Polyomavirus 9mer Epitope T Cell Responses. Am J Transplant (2016) 0.80
BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition. BMC Nephrol (2013) 0.80
Sequence Variation in Amplification Target Genes and Standards Influences Interlaboratory Comparison of BK Virus DNA Load Measurement. J Clin Microbiol (2015) 0.78
Reduced tumorigenicity and pathogenicity of cervical carcinoma SiHa cells selected for resistance to cidofovir. Mol Cancer (2013) 0.77
Effect of Leflunomide, Cidofovir and Ciprofloxacin on replication of BKPyV in a salivary gland in vitro culture system. Antiviral Res (2015) 0.76
Caveolin- and clathrin-independent entry of BKPyV into primary human proximal tubule epithelial cells. Virology (2016) 0.75
BK Virus and Nephropathy in Kidney Transplant Recipients. Int J Organ Transplant Med (2016) 0.75
Possible antiviral effect of ciprofloxacin treatment on polyomavirus BK replication and analysis of non-coding control region sequences. Virol J (2013) 0.75
BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies. Clin Microbiol Rev (2017) 0.75
High-level viruria as a screening tool for BK virus nephropathy in renal transplant recipients. Kidney Res Clin Pract (2016) 0.75
Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus Extracts Effectively Inhibit BK Virus and JC Virus Infection of Host Cells. Evid Based Complement Alternat Med (2017) 0.75
Alloimmunity But Not Viral Immunity Promotes Allograft Loss in a Mouse Model of Polyomavirus-Associated Allograft Injury. Transplant Direct (2017) 0.75
Identification of Rab18 as an Essential Host Factor for BK Polyomavirus Infection Using a Whole-Genome RNA Interference Screen. mSphere (2017) 0.75
KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant (2009) 6.43
Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med (2002) 5.34
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation (2005) 3.57
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis (2009) 3.23
Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant (2005) 2.76
Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis (2005) 2.40
Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet (1999) 2.24
Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant (2005) 2.19
Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant (2007) 2.15
Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol (2002) 1.97
Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol (2006) 1.75
Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation (2009) 1.66
Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant (2004) 1.64
Polyomavirus allograft nephropathy: sequential assessment of histologic viral load, tubulitis, and graft function following changes in immunosuppression. Am J Transplant (2003) 1.64
Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant (2007) 1.61
Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J Clin Microbiol (2008) 1.60
Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med (2008) 1.60
Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res (2009) 1.55
Detection of polyomavirus BK reactivation after renal transplantation using an intensive decoy cell surveillance program is cost-effective. Transplantation (2011) 1.52
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
Higher levels of leflunomide are associated with hemolysis and are not superior to lower levels for BK virus clearance in renal transplant patients. Clin J Am Soc Nephrol (2008) 1.45
BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant (2010) 1.43
Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant (2006) 1.42
BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen. Transpl Infect Dis (2010) 1.40
Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation (2006) 1.38
BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int (2005) 1.34
Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant (2010) 1.33
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother (1995) 1.32
BK virus in solid organ transplant recipients. Am J Transplant (2009) 1.32
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res (2007) 1.32
Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation (2005) 1.32
An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation (2009) 1.31
Early events during BK virus entry and disassembly. J Virol (2008) 1.30
BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol (2008) 1.25
Inhibition of cytomegalovirus in vitro and in vivo by the experimental immunosuppressive agent leflunomide. Intervirology (1999) 1.23
Pharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteers. Antimicrob Agents Chemother (1993) 1.23
Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. Transplantation (2009) 1.21
Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation (2006) 1.20
Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother (2006) 1.18
Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation (2007) 1.17
Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant (2008) 1.14
Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant (2008) 1.13
Functional analysis of polyomavirus BK non-coding control region quasispecies from kidney transplant recipients. J Med Virol (2009) 1.11
BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant (2011) 1.09
Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant (2005) 1.09
longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients. Clin Vaccine Immunol (2008) 1.09
Conformational rearrangements of SV40 large T antigen during early replication events. J Mol Biol (2010) 1.05
Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation (2008) 1.05
Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol (2010) 1.04
Leflunomide inhibition of BK virus replication in renal tubular epithelial cells. J Virol (2009) 1.04
BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat Rev Nephrol (2011) 1.03
Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol (2009) 1.03
Polyomavirus BK neutralizing activity in human immunoglobulin preparations. Transplantation (2010) 1.02
Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation (2010) 1.02
Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation (2008) 1.02
Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int (2009) 1.01
Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol (2007) 1.01
Sustained BK viruria as an early marker for the development of BKV-associated nephropathy: analysis of 4128 urine and serum samples. Transplantation (2009) 1.01
Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res (2011) 1.01
The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando) (2011) 1.00
1-O-hexadecyloxypropyl cidofovir (CMX001) effectively inhibits polyomavirus BK replication in primary human renal tubular epithelial cells. Antimicrob Agents Chemother (2010) 1.00
Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol (2005) 0.99
Validation of noninvasive diagnosis of BK virus nephropathy and identification of prognostic biomarkers. Transplantation (2010) 0.99
Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int (2007) 0.98
In vitro effect of cyclosporin A on primary and chronic BK polyoma virus infection in Vero E6 cells. Transpl Infect Dis (2008) 0.98
BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation (2007) 0.98
Prospective monitoring of BK virus replication in renal transplant recipients. Transpl Infect Dis (2008) 0.97
Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther (2007) 0.97
Monitoring of polyomavirus BK virus viruria and viremia in renal allograft recipients by use of a quantitative real-time PCR assay: one-year prospective study. J Clin Microbiol (2007) 0.96
BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis. Am J Transplant (2005) 0.96
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant (2009) 0.95
Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol (2008) 0.95
Monitoring of BK viral load in renal allograft recipients by real-time PCR assays. Am J Clin Pathol (2010) 0.95
Monitoring of BK virus replication in the first year following renal transplantation. Nephrol Dial Transplant (2008) 0.95
Anti-BK virus mechanisms of sirolimus and leflunomide alone and in combination: toward a new therapy for BK virus infection. Transplantation (2010) 0.93
Anti-BK virus activity of ciprofloxacin and related antibiotics. Clin Infect Dis (2005) 0.93
Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: a comparison of two reduction strategies. Clin J Am Soc Nephrol (2008) 0.93
Mutations in the external loops of BK virus VP1 and urine viral load in renal transplant recipients. J Cell Physiol (2010) 0.92
Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant (2008) 0.91
BK-VP3 as a new target of cellular immunity in BK virus infection. Transplantation (2011) 0.91
A suppressive effect of cyclosporine A on replication and noncoding control region activation of polyomavirus BK virus. Transplantation (2010) 0.90
Quantitative viral load measurement for BKV infection in renal transplant recipients as a predictive tool for BKVAN. New Microbiol (2011) 0.90
Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation (2008) 0.89
Dendritic cell deficiency associated with development of BK viremia and nephropathy in renal transplant recipients. Transplantation (2010) 0.89
Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis (2011) 0.89
Genomic mutations of viral protein 1 and BK virus nephropathy in kidney transplant recipients. J Med Virol (2009) 0.88
Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant (2010) 0.86
Antiviral therapy for polyomavirus-associated nephropathy after renal transplantation. J Antimicrob Chemother (2008) 0.86
Transforming growth factor-beta-mediated regulation of BK virus gene expression. Virology (2008) 0.86
BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol (2007) 0.85
The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol Dial Transplant (2008) 0.85
Intermediate dose cidofovir does not cause additive nephrotoxicity in BK virus allograft nephropathy. Pediatr Transplant (2008) 0.85
Monitoring the progress of BK virus associated nephropathy in renal transplant recipients. Nephrol Dial Transplant (2004) 0.85
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol (2010) 0.85
Therapeutic implications of renal anionic drug transporters. Pharmacol Ther (2010) 0.84
Screening for polyomavirus associated nephropathy in renal transplantation with blood viral load measurement. J Clin Virol (2009) 0.83
Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation (2010) 0.83